Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI
Status:
Completed
Trial end date:
2019-07-03
Target enrollment:
Participant gender:
Summary
The innovative drug XC221 is planned for use in treatment of acute respiratory viral
infections in a double-blind, randomized, placebo-controlled, comparative multicenter study
assessing the safety, tolerability and efficacy of XC221 at a dose of 200 mg per day in
patients with uncomplicated influenza or other acute respiratory viral infections during the
3-days treatment.